It was subsequently described as a marker of high reconstitution potential, within both CD34– and CD34+ subsets (Pabst et al., 2016), and reported as higher expressed in the CD34+ CD38– AML compartment, enriched in LSC (Daga et al., 2019). Here, CD34 is linked to acute myeloid leukemia.